IFNG and neoplasm: In vitro, TIM-3 blockade enhances NK cell cytotoxicity against cancer cell lines and primary multiple myeloma cells, accompanied by increased IFN-γ production; in vivo, this corresponds to reduced tumour growth (184, 185).